Rhinitis, sinusitis, and upper airway diseaseFel d 1–derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: A randomized, placebo-controlled study
Key words
Abbreviations used
Cited by (0)
Supported by Adiga Life Sciences and Circassia. M.L. is supported by the Canada Research Chairs program, the Canadian Foundation for Innovation, and the McMaster University/GlaxoSmithKline Chair in Lung Immunology at St Joseph’s Healthcare.
Disclosure of potential conflict of interest: D. Patel and P. Couroux are employed by Cetero Research. P. Hickey, P. Laidler, and R. P. Hafner are employed by Circassia Limited. A. M. Salapatek was employed by Cetero Research and has received research support from Circassia Research. M. Larché is founder, consultant, and stockholder of Circassia Limited; is scientific founder of Adiga Life Sciences; has consultant arrangements with Boehringer Ingelheim; has received one or more honoraria from MedImmune; has received research support from Adiga Life Sciences, the Canadian Institutes for Health Research, the Canadian Lung Association, the Canada Research Chairs program, and the McMaster University/GlaxoSmithKline Chair in Lung Immunology at St Joseph's Healthcare; and is a member of the American Academy of Allergy, Asthma & Immunology Genetics, Molecular Biology, and Epidemiology Committee.
- ∗
Drs Patel and Couroux are currently affiliated with Topstone Research, Toronto, Ontario, Canada.
- ‡
Dr Salapatek is currently affiliated with Adiga Life Sciences, Hamilton, Ontario, Canada.